title: Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.
abstract: OBJECTIVE
  Providing epidemiological data and treatment of anemia in lung cancer patients undergoing first-line chemotherapy.
  
  
  METHODS
  Epidemiological, observational, retrospective and multicenter study carried out at 30 sites throughout Spain.
  
  
  RESULTS
  The prevalence of anemia (hemoglobin [Hb] level <12 g/dl) was 18.3% and the incidence 80.7%. Mean Hb levels were 13.4 g/dl (95% Cl: 13.2-13.6) and 11.5 g/dl (95% Cl: 11.3-11.7) at starting and at the end of chemotherapy, respectively. Of the 294 patients with anemia, 174 (59.2%) were treated. Erythropoiesis-stimulating agents were given to 90.2% patients, alone in 31.6% and combined iron in 39.7%, transfusion in 9.2% and iron and transfusion in 9.8%.
  
  
  CONCLUSIONS
  These results suggest an appropriate and rational use of erythropoiesis-stimulating agents in the treatment of chemotherapy-associated anemia in lung cancer patients. [corrected].
authors.affiliation: 1Hospital Doctor Peset, Valencia, Spain.
authors.forename: Jose
authors.initials: J
authors.lastname: Muñoz-Langa
authors.affiliation: 2Hospital La Paz, Madrid, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: De Castro
authors.affiliation: 3Hospital Clinic i Provincial, Barcelona, Spain.
authors.forename: Pere
authors.initials: P
authors.lastname: Gascó
authors.affiliation: 4Hospital Provincial de Castellón, Spain.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Sanchez
authors.affiliation: 5Hospital Central Asturias, Oviedo, Spain.
authors.forename: Emilio
authors.initials: E
authors.lastname: Esteban
authors.affiliation: 6Hospital Marina Alta, Denia, Spain.
authors.forename: Jose Manuel
authors.initials: JM
authors.lastname: Gasent
authors.affiliation: 7Hospital Reina Sofía, Murcia, Spain.
authors.forename: Isidoro
authors.initials: I
authors.lastname: Barneto
authors.affiliation: 8Hospital La Fé, Valencia, Spain.
authors.forename: Joaquin
authors.initials: J
authors.lastname: Montalar
authors.affiliation: 9Hospital Miguel Servet, Zaragoza, Spain.
authors.forename: Angel
authors.initials: A
authors.lastname: Artal
authors.affiliation: 10Jansssen-Cilag, Madrid, Spain.
authors.forename: Sara
authors.initials: S
authors.lastname: Vidal
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced / Q000453:epidemiology* / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D000068258:Bevacizumab / Q000008:administration & dosage; D001803:Blood Transfusion; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D015994:Incidence; D007501:Iron / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D064887:Observational Studies as Topic; D015995:Prevalence; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*; D013030:Spain / Q000453:epidemiology; D043823:Taxoids / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D055815:Young Adult; D000093542:Gemcitabine
chemical_list: D001952:Bridged-Ring Compounds; D006397:Hematinics; D006454:Hemoglobins; D043823:Taxoids; D003841:Deoxycytidine; C080625:taxane; D000068258:Bevacizumab; D014747:Vinblastine; D005047:Etoposide; D016190:Carboplatin; D007501:Iron; D002945:Cisplatin; D000077235:Vinorelbine; D000093542:Gemcitabine
keywords: anemia; chemotherapy; erythropoietin-stimulating agents; iron; lung cancer; transfusion